The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 35 | — | 20.1x | Near average | |
Growth | 29 | -55.2% | 5.6% | Below average | |
Quality | 75 | 116.0% | 7.6% | Above average | |
Safety | 57 | 0.1x | 0.4x | Near average | |
Capital Return | 14 | — | 2.19% | Below average | |
Momentum | 59 | — | — | Near average | |
Sentiment | 40 | — | — | Near average |
Innate Pharma S.A. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Innate Pharma S.A. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Innate Pharma stock has witnessed a notable decline in the average price target by 30% over the past thirty days, dropping from $5 to $3.5. This negative adjustment coincided with an increase in the number of analysts covering the stock from one to three, leading to a wider Dispersion between a low of $2 and a high of $5, reflecting a state of uncertainty regarding the future valuation.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.